Replimune Group, Inc.
REPLHealthcareNASDAQBiotechnology · Last scanned Jul 16, 2026
Scan Results
Daily timeframeReplimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer in the United States and the United Kingdom. At a $812.6M market cap, Replimune Group, Inc. ranks as a small-cap company within healthcare. The company's proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer.
Market Cap
$812.6M
Beta
0.87
P/E (TTM)
—
P/E (Fwd)
-8.39
EPS (TTM)
$-3.32
EPS (Fwd)
$-1.15
ROE
-107.9%
ROA
-45.0%
Cash
$268.9M
Total Debt
$111.6M
Free CF
-$172.2M
52W Change
-23.4%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $268.9M in cash comfortably exceeding the $111.6M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. The company is burning cash, with free cash flow at -$172.2M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -107.9%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing REPL.